Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5197860
Max Phase: Preclinical
Molecular Formula: C26H40O2
Molecular Weight: 384.60
Associated Items:
ID: ALA5197860
Max Phase: Preclinical
Molecular Formula: C26H40O2
Molecular Weight: 384.60
Associated Items:
Canonical SMILES: CC(=C/C=C/C(C)=C/C(=O)O)/C=C1\CCCC(CCC(C)C)=C1CCC(C)C
Standard InChI: InChI=1S/C26H40O2/c1-19(2)13-15-23-11-8-12-24(25(23)16-14-20(3)4)17-21(5)9-7-10-22(6)18-26(27)28/h7,9-10,17-20H,8,11-16H2,1-6H3,(H,27,28)/b10-7+,21-9-,22-18+,24-17+
Standard InChI Key: SXJCTSSRCWXFCW-XGDCXREESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 384.60 | Molecular Weight (Monoisotopic): 384.3028 | AlogP: 7.80 | #Rotatable Bonds: 10 |
Polar Surface Area: 37.30 | Molecular Species: ACID | HBA: 1 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 2 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 4.56 | CX Basic pKa: | CX LogP: 7.47 | CX LogD: 4.71 |
Aromatic Rings: 0 | Heavy Atoms: 28 | QED Weighted: 0.31 | Np Likeness Score: 1.25 |
1. Atigadda VR, Kashyap MP, Yang Z, Chattopadhyay D, Melo N, Sinha R, Belyaeva OV, Chou CF, Chang PL, Kedishvili NY, Grubbs CJ, Renfrow MB, Muccio DD, Elmets CA, Athar M.. (2022) Conformationally Defined Rexinoids for the Prevention of Inflammation and Nonmelanoma Skin Cancers., 65 (21.0): [PMID:36318154] [10.1021/acs.jmedchem.2c00735] |
Source(1):